{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T01:17:41Z","timestamp":1790990261475,"version":"4.1.0"},"reference-count":149,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2020,3,18]],"date-time":"2020-03-18T00:00:00Z","timestamp":1584489600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003243","name":"Ministerstvo Zdravotnictv\u00ed Cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["AZV 17-28980A"],"award-info":[{"award-number":["AZV 17-28980A"]}],"id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001824","name":"Grantov\u00e1 Agentura \u010cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["GA20-25308S"],"award-info":[{"award-number":["GA20-25308S"]}],"id":[{"id":"10.13039\/501100001824","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007397","name":"Univerzita Karlova v Praze","doi-asserted-by":"publisher","award":["Center of Excellence UNCE\/MED\/16"],"award-info":[{"award-number":["Center of Excellence UNCE\/MED\/16"]}],"id":[{"id":"10.13039\/100007397","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007397","name":"Univerzita Karlova v Praze","doi-asserted-by":"publisher","award":["PRIMUS 19\/MED\/07"],"award-info":[{"award-number":["PRIMUS 19\/MED\/07"]}],"id":[{"id":"10.13039\/100007397","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001823","name":"Ministerstvo \u0160kolstv\u00ed, Ml\u00e1de\u017ee a T\u011blov\u00fdchovy","doi-asserted-by":"publisher","award":["PROGRES Q26\/LF1"],"award-info":[{"award-number":["PROGRES Q26\/LF1"]}],"id":[{"id":"10.13039\/501100001823","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001823","name":"Ministerstvo \u0160kolstv\u00ed, Ml\u00e1de\u017ee a T\u011blov\u00fdchovy","doi-asserted-by":"publisher","award":["PROGRES Q28\/LF1"],"award-info":[{"award-number":["PROGRES Q28\/LF1"]}],"id":[{"id":"10.13039\/501100001823","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Non-Hodgkin lymphomas (NHL) are lymphoid tumors that arise by a complex process of malignant transformation of mature lymphocytes during various stages of differentiation. The WHO classification of NHL recognizes more than 90 nosological units with peculiar pathophysiology and prognosis. Since the end of the 20th century, our increasing knowledge of the molecular biology of lymphoma subtypes led to the identification of novel druggable targets and subsequent testing and clinical approval of novel anti-lymphoma agents, which translated into significant improvement of patients\u2019 outcome. Despite immense progress, our effort to control or even eradicate malignant lymphoma clones has been frequently hampered by the development of drug resistance with ensuing unmet medical need to cope with relapsed or treatment-refractory disease. A better understanding of the molecular mechanisms that underlie inherent or acquired drug resistance might lead to the design of more effective front-line treatment algorithms based on reliable predictive markers or personalized salvage therapy, tailored to overcome resistant clones, by targeting weak spots of lymphoma cells resistant to previous line(s) of therapy. This review focuses on the history and recent advances in our understanding of molecular mechanisms of resistance to genotoxic and targeted agents used in clinical practice for the therapy of NHL.<\/jats:p>","DOI":"10.3390\/ijms21062081","type":"journal-article","created":{"date-parts":[[2020,3,19]],"date-time":"2020-03-19T03:54:14Z","timestamp":1584590054000},"page":"2081","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":66,"title":["Drug Resistance in Non-Hodgkin Lymphomas"],"prefix":"10.3390","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7786-9378","authenticated-orcid":false,"given":"Pavel","family":"Klener","sequence":"first","affiliation":[{"name":"First Department of Internale Medicine-Hematology, University General Hospital in Prague, 128 08 Prague, Czech Republic"},{"name":"Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, 128 53 Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Klanova","sequence":"additional","affiliation":[{"name":"First Department of Internale Medicine-Hematology, University General Hospital in Prague, 128 08 Prague, Czech Republic"},{"name":"Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, 128 53 Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,3,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Swerdlow, S.H., and Cook, J.R. (2019). As the world turns, evolving lymphoma classifications-past, present and future. Hum. Pathol.","DOI":"10.1016\/j.humpath.2019.08.019"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"342","DOI":"10.3322\/canjclin.21.6.342","article-title":"The management of lymphoma","volume":"21","author":"Ultmann","year":"1971","journal-title":"CA A Cancer J. Clin."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/1097-0142(197108)28:2<306::AID-CNCR2820280208>3.0.CO;2-N","article-title":"Combined cyclophosphamide vincristine, and prednisone therapy of malignant lymphoma","volume":"28","author":"Luce","year":"1971","journal-title":"Cancer"},{"key":"ref_5","first-page":"230","article-title":"Adriamycin and other anthracycline antibiotics under study in the United States","volume":"63","author":"Benjamin","year":"1978","journal-title":"Recent Results Cancer Res. Fortschr. Der Krebsforsch. Prog. Dans Les Rech. Sur Le Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1056\/NEJM198503143121106","article-title":"Etoposide (VP-16-213). Current status of an active anticancer drug","volume":"312","author":"Alonso","year":"1985","journal-title":"N. Engl. J. Med."},{"key":"ref_7","first-page":"1","article-title":"Chemotherapy of malignant lymphomas","volume":"12","author":"Bonadonna","year":"1985","journal-title":"Semin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1200\/JCO.1991.9.1.175","article-title":"Fludarabine phosphate: A synthetic purine antimetabolite with significant activity against lymphoid malignancies","volume":"9","author":"Chun","year":"1991","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1200\/JCO.1997.15.10.3266","article-title":"IDEC-C2B8: Results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin\u2019s lymphoma","volume":"15","author":"Maloney","year":"1997","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3389\/fonc.2018.00163","article-title":"Past, Present, and Future of Rituximab-The World\u2019s First Oncology Monoclonal Antibody Therapy","volume":"8","author":"Pierpont","year":"2018","journal-title":"Front. Oncol."},{"key":"ref_11","first-page":"1927","article-title":"Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study","volume":"92","author":"Coiffier","year":"1998","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1200\/JCO.2001.19.2.389","article-title":"Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin\u2019s lymphoma","volume":"19","author":"Vose","year":"2001","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1200\/JCO.1999.17.1.268","article-title":"Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy","volume":"17","author":"Czuczman","year":"1999","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","article-title":"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): A phase 3, randomised controlled trial","volume":"377","author":"Salles","year":"2011","journal-title":"Lancet"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1056\/NEJMoa1701769","article-title":"Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma","volume":"377","author":"Thieblemont","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Freedman, A., and Jacobsen, E. (2019). Follicular lymphoma: 2020 update on diagnosis and management. Am. J. Hematol.","DOI":"10.1002\/ajh.25696"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1158\/2159-8290.CD-18-1393","article-title":"Mechanisms of Lymphoma Clearance Induced by High-Dose Alkylating Agents","volume":"9","author":"Lossos","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.4049\/jimmunol.0713732","article-title":"M2 macrophages phagocytose rituximab-opsonized leukemic targets more efficiently than m1 cells in vitro","volume":"182","author":"Leidi","year":"2009","journal-title":"J. Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1016\/S1470-2045(16)30030-4","article-title":"Antibody-drug conjugates for cancer therapy","volume":"17","author":"Thomas","year":"2016","journal-title":"Lancet. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","article-title":"Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: Results of a phase II study","volume":"30","author":"Pro","year":"2012","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): A global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1365-2141.2009.07740.x","article-title":"A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma","volume":"146","author":"Leonard","year":"2009","journal-title":"Br. J. Haematol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0140-6736(17)31266-7","article-title":"Brentuximab vedotin or physician\u2019s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): An international, open-label, randomised, phase 3, multicentre trial","volume":"390","author":"Prince","year":"2017","journal-title":"Lancet"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Sehn, L.H., Herrera, A.F., Flowers, C.R., Kamdar, M.K., McMillan, A., Hertzberg, M., Assouline, S., Kim, T.M., Kim, W.S., and Ozcan, M. (2019). Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.","DOI":"10.1200\/JCO.19.00172"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1007\/s40265-018-1000-9","article-title":"Moxetumomab Pasudotox: First Global Approval","volume":"78","author":"Dhillon","year":"2018","journal-title":"Drugs"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s13045-019-0786-6","article-title":"Antibody-drug conjugates in clinical trials for lymphoid malignancies and multiple myeloma","volume":"12","author":"Yu","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","article-title":"Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome","volume":"344","author":"Druker","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","article-title":"Ibrutinib in previously treated Waldenstrom\u2019s macroglobulinemia","volume":"372","author":"Treon","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e233","DOI":"10.3747\/co.26.4345","article-title":"Review of Bruton tyrosine kinase inhibitors for the treatment of relapsed or refractory mantle cell lymphoma","volume":"26","author":"Owen","year":"2019","journal-title":"Curr. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","article-title":"PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma","volume":"370","author":"Gopal","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1093\/annonc\/mdx289","article-title":"Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma","volume":"28","author":"Dreyling","year":"2017","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1200\/JCO.2017.75.4648","article-title":"Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma","volume":"35","author":"Dreyling","year":"2017","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Dreyling, M., Santoro, A., Mollica, L., Leppa, S., Follows, G., Lenz, G., Kim, W.S., Nagler, A., Dimou, M., and Demeter, J. (2019). Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study. Am. J. Hematol.","DOI":"10.1002\/ajh.25711"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1182\/blood.2019001795","article-title":"Duvelisib for CLL\/SLL and follicular non-Hodgkin lymphoma","volume":"134","author":"Patel","year":"2019","journal-title":"Blood"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1200\/JCO.18.00915","article-title":"DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma","volume":"37","author":"Flinn","year":"2019","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s11899-019-00540-w","article-title":"The Role of PI3K Inhibition in Lymphoid Malignancies","volume":"14","author":"Moskowitz","year":"2019","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Lemm, E.A., Valle-Argos, B., Smith, L.D., Richter, J., Gebreselassie, Y., Carter, M.J., Karolova, J., Svaton, M., Helman, K., and Weston-Bell, N.J. (2019). Preclinical evaluation of a novel SHIP1 phosphatase activator for inhibition of PI3K signaling in malignant B-cells. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res.","DOI":"10.1158\/1078-0432.CCR-19-2202"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/bjh.14529","article-title":"m-TOR inhibitors and their potential role in haematological malignancies","volume":"177","author":"Calimeri","year":"2017","journal-title":"Br. J. Haematol."},{"key":"ref_43","first-page":"432","article-title":"Deep sequencing reveals clonal evolution patterns and mutation events associated with relapse in B-cell lymphomas","volume":"15","author":"Jiang","year":"2014","journal-title":"Genome Biol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1038\/leu.2016.135","article-title":"Distinct genetic evolution patterns of relapsing diffuse large B-cell lymphoma revealed by genome-wide copy number aberration and targeted sequencing analysis","volume":"30","author":"Juskevicius","year":"2016","journal-title":"Leukemia"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.3324\/haematol.2016.151647","article-title":"Genetic background and evolution of relapses in aggressive B-cell lymphomas","volume":"102","author":"Juskevicius","year":"2017","journal-title":"Haematologica"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1097\/MOH.0000000000000258","article-title":"Genetic and epigenetic determinants of B-cell lymphoma evolution","volume":"23","author":"Izzo","year":"2016","journal-title":"Curr. Opin. Hematol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes","volume":"24","author":"Chapuy","year":"2018","journal-title":"Nat. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1038\/nm.3940","article-title":"Disruption of KMT2D perturbs germinal center B cell development and promotes lymphomagenesis","volume":"21","author":"Zhang","year":"2015","journal-title":"Nat. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.ccr.2013.04.011","article-title":"EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation","volume":"23","author":"Beguelin","year":"2013","journal-title":"Cancer Cell"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1002\/path.5043","article-title":"Novel insights into the disease dynamics of B-cell lymphomas in the Genomics Era","volume":"244","author":"Chan","year":"2018","journal-title":"J. Pathol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"9406","DOI":"10.1038\/s41598-019-45882-w","article-title":"Cell population heterogeneity driven by stochastic partition and growth optimality","volume":"9","author":"Mulet","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1159\/000475530","article-title":"Tumor Heterogeneity in Lymphomas: A Different Breed","volume":"85","author":"Schurch","year":"2018","journal-title":"Pathobiol. J. Immunopathol. Mol. Cell. Biol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1126\/science.aav4474","article-title":"Adaptive mutability of colorectal cancers in response to targeted therapies","volume":"366","author":"Russo","year":"2019","journal-title":"Science"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.cell.2010.02.027","article-title":"A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations","volume":"141","author":"Sharma","year":"2010","journal-title":"Cell"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1038\/nm.4409","article-title":"Cancer stem cells revisited","volume":"23","author":"Batlle","year":"2017","journal-title":"Nat. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/nature12624","article-title":"Tumour heterogeneity and cancer cell plasticity","volume":"501","author":"Meacham","year":"2013","journal-title":"Nature"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/stem.1035","article-title":"Role of BMI1, a stem cell factor, in cancer recurrence and chemoresistance: Preclinical and clinical evidences","volume":"30","author":"Siddique","year":"2012","journal-title":"Stem Cells"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1002\/gcc.22088","article-title":"BMI1, the polycomb-group gene, is recurrently targeted by genomic rearrangements in progressive B-cell leukemia\/lymphoma","volume":"52","author":"Rouhigharabaei","year":"2013","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_60","first-page":"2409","article-title":"BMI-1 gene amplification and overexpression in hematological malignancies occur mainly in mantle cell lymphomas","volume":"61","author":"Bea","year":"2001","journal-title":"Cancer Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1038\/onc.2013.177","article-title":"Dysregulation of BMI1 and microRNA-16 collaborate to enhance an anti-apoptotic potential in the side population of refractory mantle cell lymphoma","volume":"33","author":"Teshima","year":"2014","journal-title":"Oncogene"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1080\/10428194.2017.1410883","article-title":"Abundant expression of BMI1 in follicular lymphoma is associated with reduced overall survival","volume":"59","author":"AlJohani","year":"2018","journal-title":"Leuk. Lymphoma"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"107-118.e2","DOI":"10.1016\/j.exphem.2011.10.004","article-title":"Bortezomib-resistant nuclear factor kappaB expression in stem-like cells in mantle cell lymphoma","volume":"40","author":"Jung","year":"2012","journal-title":"Exp. Hematol."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Wu, C., Gupta, N., Huang, Y.H., Zhang, H.F., Alshareef, A., Chow, A., and Lai, R. (2018). Oxidative stress enhances tumorigenicity and stem-like features via the activation of the Wnt\/beta-catenin\/MYC\/Sox2 axis in ALK-positive anaplastic large-cell lymphoma. BMC Cancer, 18.","DOI":"10.1186\/s12885-018-4300-2"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41375-019-0497-6","article-title":"Loss of KDM6A confers drug resistance in acute myeloid leukemia","volume":"34","author":"Stief","year":"2019","journal-title":"Leukemia"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"269","DOI":"10.2217\/pgs.11.149","article-title":"Cytidine deaminase genetic variants influence RNA expression and cytarabine cytotoxicity in acute myeloid leukemia","volume":"13","author":"Abraham","year":"2012","journal-title":"Pharmacogenomics"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/1476-4598-13-159","article-title":"Downregulation of deoxycytidine kinase in cytarabine-resistant mantle cell lymphoma cells confers cross-resistance to nucleoside analogs gemcitabine, fludarabine and cladribine, but not to other classes of anti-lymphoma agents","volume":"13","author":"Klanova","year":"2014","journal-title":"Mol. Cancer"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1200\/JCO.1991.9.1.17","article-title":"P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil","volume":"9","author":"Miller","year":"1991","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"e1593","DOI":"10.1038\/cddis.2014.525","article-title":"MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K\/AKT\/mTOR activation in lymphoid malignancies","volume":"6","author":"Choudhary","year":"2015","journal-title":"Cell Death Dis."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1038\/leu.2012.81","article-title":"Mast cells promote the growth of Hodgkin\u2019s lymphoma cell tumor by modifying the tumor microenvironment that can be perturbed by bortezomib","volume":"26","author":"Mizuno","year":"2012","journal-title":"Leukemia"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"King, R.L., Goodlad, J.R., Calaminici, M., Dotlic, S., Montes-Moreno, S., Oschlies, I., Ponzoni, M., Traverse-Glehen, A., Ott, G., and Ferry, J.A. (2019). Lymphomas arising in immune-privileged sites: Insights into biology, diagnosis, and pathogenesis. Virchows Arch. Int. J. Pathol.","DOI":"10.1007\/s00428-019-02698-3"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jconrel.2018.09.018","article-title":"Effective doxorubicin-based nano-therapeutics for simultaneous malignant lymphoma treatment and lymphoma growth imaging","volume":"289","author":"Etrych","year":"2018","journal-title":"J. Control. Release Off. J. Control. Release Soc."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1200\/JCO.2017.77.6112","article-title":"CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia","volume":"36","author":"Lancet","year":"2018","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nature13034","article-title":"Direct measurement of local oxygen concentration in the bone marrow of live animals","volume":"508","author":"Spencer","year":"2014","journal-title":"Nature"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s12943-019-1089-9","article-title":"Role of hypoxia in cancer therapy by regulating the tumor microenvironment","volume":"18","author":"Jing","year":"2019","journal-title":"Mol. Cancer"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.3389\/fonc.2019.01277","article-title":"Sustain, Adapt, and Overcome-Hypoxia Associated Changes in the Progression of Lymphatic Neoplasia","volume":"9","author":"Matolay","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nrc.2017.77","article-title":"Tumour acidosis: From the passenger to the driver\u2019s seat","volume":"17","author":"Corbet","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/imm.12917","article-title":"Hypoxia and acidosis: Immune suppressors and therapeutic targets","volume":"154","author":"Damgaci","year":"2018","journal-title":"Immunology"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"3470","DOI":"10.4161\/cc.9.17.13048","article-title":"Targeting autophagy to fight hematopoietic malignancies","volume":"9","author":"Puissant","year":"2010","journal-title":"Cell Cycle"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"556","DOI":"10.3389\/fonc.2018.00556","article-title":"Metabolic Reprogramming of Non-Hodgkin\u2019s B-Cell Lymphomas and Potential Therapeutic Strategies","volume":"8","author":"Ricci","year":"2018","journal-title":"Front. Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1126\/science.124.3215.269","article-title":"On respiratory impairment in cancer cells","volume":"124","author":"Warburg","year":"1956","journal-title":"Science"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1042\/BST20160094","article-title":"The Warburg effect: 80 years on","volume":"44","author":"Potter","year":"2016","journal-title":"Biochem. Soc. Trans."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Burns, J.S., and Manda, G. (2017). Metabolic Pathways of the Warburg Effect in Health and Disease: Perspectives of Choice, Chain or Chance. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18122755"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/nature11066","article-title":"AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress","volume":"485","author":"Jeon","year":"2012","journal-title":"Nature"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1182\/blood-2004-07-2947","article-title":"Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response","volume":"105","author":"Monti","year":"2005","journal-title":"Blood"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.cmet.2019.02.002","article-title":"GAPDH Expression Predicts the Response to R-CHOP, the Tumor Metabolic Status, and the Response of DLBCL Patients to Metabolic Inhibitors","volume":"29","author":"Chiche","year":"2019","journal-title":"Cell Metab."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.cmet.2011.12.009","article-title":"Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells","volume":"15","author":"Le","year":"2012","journal-title":"Cell Metab."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/labinvest.2014.61","article-title":"Mouse models of mantle cell lymphoma, complex changes in gene expression and phenotype of engrafted MCL cells: Implications for preclinical research","volume":"94","author":"Klanova","year":"2014","journal-title":"Lab Investig."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1200\/JCO.1995.13.8.1995","article-title":"Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy","volume":"13","author":"Wilson","year":"1995","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1200\/JCO.1989.7.4.415","article-title":"Drug-resistance in multiple myeloma and non-Hodgkin\u2019s lymphoma: Detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy","volume":"7","author":"Dalton","year":"1989","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_91","first-page":"69","article-title":"Microenvironment acidity as a major determinant of tumor chemoresistance: Proton pump inhibitors (PPIs) as a novel therapeutic approach","volume":"23","author":"Taylor","year":"2015","journal-title":"Drug Resist. Updates Rev. Comment. Antimicrob. Anticancer Chemother."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Perez-Hernandez, M., Arias, A., Martinez-Garcia, D., Perez-Tomas, R., Quesada, R., and Soto-Cerrato, V. (2019). Targeting Autophagy for Cancer Treatment and Tumor Chemosensitization. Cancers, 11.","DOI":"10.3390\/cancers11101599"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.diabet.2019.05.002","article-title":"Metformin is associated with a lower risk of non-Hodgkin lymphoma in patients with type 2 diabetes","volume":"45","author":"Tseng","year":"2019","journal-title":"Diabetes Metab."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.amjms.2019.06.002","article-title":"Metformin Associated With Increased Survival in Type 2 Diabetes Patients With Pancreatic Cancer and Lymphoma","volume":"358","author":"Wynn","year":"2019","journal-title":"Am. J. Med Sci."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ccell.2019.07.007","article-title":"LMO2 Confers Synthetic Lethality to PARP Inhibition in DLBCL","volume":"36","author":"Parvin","year":"2019","journal-title":"Cancer Cell"},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Chen, S.H., and Chang, J.Y. (2019). New Insights into Mechanisms of Cisplatin Resistance: From Tumor Cell to Microenvironment. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20174136"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/onc.2011.384","article-title":"Molecular mechanisms of cisplatin resistance","volume":"31","author":"Galluzzi","year":"2012","journal-title":"Oncogene"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s12185-017-2226-0","article-title":"DNA damage response and hematological malignancy","volume":"106","author":"Takagi","year":"2017","journal-title":"Int. J. Hematol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"3668","DOI":"10.1182\/blood-2011-11-366062","article-title":"Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies","volume":"119","author":"Medeiros","year":"2012","journal-title":"Blood"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1038\/modpathol.2017.58","article-title":"Clinical utility of recently identified diagnostic, prognostic, and predictive molecular biomarkers in mature B-cell neoplasms","volume":"30","author":"Onaindia","year":"2017","journal-title":"Mod. Pathol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1182\/blood-2018-07-862862","article-title":"Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL","volume":"133","author":"Klanova","year":"2019","journal-title":"Blood"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/blood-2009-10-247122","article-title":"Diffuse large B-cell lymphomas with CDKN2A deletion have a distinct gene expression signature and a poor prognosis under R-CHOP treatment: A GELA study","volume":"116","author":"Jardin","year":"2010","journal-title":"Blood"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1182\/blood-2015-02-628792","article-title":"High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma","volume":"126","author":"Klapper","year":"2015","journal-title":"Blood"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1182\/blood-2009-01-198580","article-title":"Follicular lymphomas with and without translocation t(14;18) differ in gene expression profiles and genetic alterations","volume":"114","author":"Leich","year":"2009","journal-title":"Blood"},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Klanova, M., Andera, L., Brazina, J., Svadlenka, J., Benesova, S., Soukup, J., Prukova, D., Vejmelkova, D., Jaksa, R., and Helman, K. (2015). Targeting of BCL2 Family Proteins with ABT-199 and Homoharringtonine Reveals BCL2- and MCL1-Dependent Subgroups of Diffuse Large B-Cell Lymphoma. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res.","DOI":"10.1158\/1078-0432.CCR-15-1191"},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Prukova, D., Andera, L., Nahacka, Z., Karolova, J., Svaton, M., Klanova, M., Havranek, O., Soukup, J., Svobodova, K., and Zemanova, Z. (2019). Co-targeting of BCL2 with venetoclax and MCL1 with S63845 is synthetically lethal in vivo in relapsed mantle cell lymphoma. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res.","DOI":"10.1158\/1078-0432.CCR-18-3275"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.humpath.2019.08.008","article-title":"Proapoptotic protein BIM as a novel prognostic marker in mantle cell lymphoma","volume":"93","author":"Wang","year":"2019","journal-title":"Hum. Pathol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1182\/blood-2011-12-395673","article-title":"Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia","volume":"119","author":"Rossi","year":"2012","journal-title":"Blood"},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Ho, C.J., and Gorski, S.M. (2019). Molecular Mechanisms Underlying Autophagy-Mediated Treatment Resistance in Cancer. Cancers, 11.","DOI":"10.3390\/cancers11111775"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1007\/s12185-018-2414-6","article-title":"Targeting autophagy in lymphomas: A double-edged sword?","volume":"107","author":"Zhang","year":"2018","journal-title":"Int. J. Hematol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s10020-018-0033-6","article-title":"AEG-1 is involved in hypoxia-induced autophagy and decreases chemosensitivity in T-cell lymphoma","volume":"24","author":"Yan","year":"2018","journal-title":"Mol. Med."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"6410","DOI":"10.1158\/0008-5472.CAN-16-0595","article-title":"TG2 and NF-kappaB Signaling Coordinates the Survival of Mantle Cell Lymphoma Cells via IL6-Mediated Autophagy","volume":"76","author":"Zhang","year":"2016","journal-title":"Cancer Res."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"5278","DOI":"10.1158\/1078-0432.CCR-12-0351","article-title":"Counteracting autophagy overcomes resistance to everolimus in mantle cell lymphoma","volume":"18","author":"Rosich","year":"2012","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1158\/1078-0432.CCR-15-0987","article-title":"ROS-Induced CXCR4 Signaling Regulates Mantle Cell Lymphoma (MCL) Cell Survival and Drug Resistance in the Bone Marrow Microenvironment via Autophagy","volume":"22","author":"Chen","year":"2016","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.2217\/pgs.09.118","article-title":"Genetic factors influencing cytarabine therapy","volume":"10","author":"Lamba","year":"2009","journal-title":"Pharmacogenomics"},{"key":"ref_116","first-page":"895","article-title":"Expression of human equilibrative nucleoside transporter 1 (hENT1) and its correlation with gemcitabine uptake and cytotoxicity in mantle cell lymphoma","volume":"91","author":"Marce","year":"2006","journal-title":"Haematologica"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(16)00739-X","article-title":"Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): A randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network","volume":"388","author":"Hermine","year":"2016","journal-title":"Lancet"},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Lorkova, L., Scigelova, M., Arrey, T.N., Vit, O., Pospisilova, J., Doktorova, E., Klanova, M., Alam, M., Vockova, P., and Maswabi, B. (2015). Detailed Functional and Proteomic Characterization of Fludarabine Resistance in Mantle Cell Lymphoma Cells. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0135314"},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Freiburghaus, C., Emruli, V.K., Johansson, A., Eskelund, C.W., Gronbaek, K., Olsson, R., Ek, F., Jerkeman, M., and Ek, S. (2018). Bortezomib prevents cytarabine resistance in MCL, which is characterized by down-regulation of dCK and up-regulation of SPIB resulting in high NF-kappaB activity. BMC Cancer, 18.","DOI":"10.1186\/s12885-018-4346-1"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"6904","DOI":"10.1182\/blood-2011-08-373159","article-title":"Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: Association with progression and fludarabine-refractoriness","volume":"118","author":"Rossi","year":"2011","journal-title":"Blood"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1182\/blood-2015-11-681460","article-title":"Pathogenic role of B-cell receptor signaling and canonical NF-kappaB activation in mantle cell lymphoma","volume":"128","author":"Saba","year":"2016","journal-title":"Blood"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1002\/ijc.29326","article-title":"Inhibitors of BCR signalling interrupt the survival signal mediated by the micro-environment in mantle cell lymphoma","volume":"136","author":"Bernard","year":"2015","journal-title":"Int. J. Cancer"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1182\/blood-2013-02-482125","article-title":"Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients","volume":"122","author":"Chang","year":"2013","journal-title":"Blood"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/bjh.12974","article-title":"Characterization of ibrutinib-sensitive and -resistant mantle lymphoma cells","volume":"166","author":"Ma","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/bjh.15108","article-title":"Ibrutinib resistance in mantle cell lymphoma: Clinical, molecular and treatment aspects","volume":"181","author":"Pulver","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"14920","DOI":"10.1038\/ncomms14920","article-title":"Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma","volume":"8","author":"Zhao","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1158\/2159-8290.CD-14-0098","article-title":"Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma","volume":"4","author":"Chiron","year":"2014","journal-title":"Cancer Discov."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"38180","DOI":"10.18632\/oncotarget.9500","article-title":"Genetic heterogeneity in primary and relapsed mantle cell lymphomas: Impact of recurrent CARD11 mutations","volume":"7","author":"Wu","year":"2016","journal-title":"Oncotarget"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1158\/1535-7163.MCT-17-0789-ATR","article-title":"XPO1 Inhibitor Selinexor Overcomes Intrinsic Ibrutinib Resistance in Mantle Cell Lymphoma via Nuclear Retention of IkappaB","volume":"17","author":"Ming","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/s41419-019-2158-0","article-title":"Resistance to BTK inhibition by ibrutinib can be overcome by preventing FOXO3a nuclear export and PI3K\/AKT activation in B-cell lymphoid malignancies","volume":"10","author":"Kapoor","year":"2019","journal-title":"Cell Death Dis."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMoa1715519","article-title":"Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma","volume":"378","author":"Tam","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/bjh.15567","article-title":"Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib","volume":"183","author":"Jain","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1182\/bloodadvances.2019000635","article-title":"CXCR4 (S338X) clonality is an important determinant of ibrutinib outcomes in patients with Waldenstrom macroglobulinemia","volume":"3","author":"Gustine","year":"2019","journal-title":"Blood Adv."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/leu.2014.187","article-title":"The WHIM-like CXCR4(S338X) somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom\u2019s Macroglobulinemia","volume":"29","author":"Cao","year":"2015","journal-title":"Leukemia"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/cas.12582","article-title":"Basal expression of insulin-like growth factor 1 receptor determines intrinsic resistance of cancer cells to a phosphatidylinositol 3-kinase inhibitor ZSTK474","volume":"106","author":"Isoyama","year":"2015","journal-title":"Cancer Sci."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1182\/blood.2018881029","article-title":"IGF1R as druggable target mediating PI3K-delta inhibitor resistance in a murine model of chronic lymphocytic leukemia","volume":"134","author":"Scheffold","year":"2019","journal-title":"Blood"},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Kim, J.H., Kim, W.S., and Park, C. (2019). Interleukin-6 mediates resistance to PI3K-pathway-targeted therapy in lymphoma. BMC Cancer, 19.","DOI":"10.1186\/s12885-019-6057-7"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1315226","article-title":"Idelalisib and rituximab in relapsed chronic lymphocytic leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S1470-2045(16)30671-4","article-title":"Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: Interim results from a phase 3, randomised, double-blind, placebo-controlled trial","volume":"18","author":"Zelenetz","year":"2017","journal-title":"Lancet. Oncol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s40265-016-0596-x","article-title":"Venetoclax: First Global Approval","volume":"76","author":"Deeks","year":"2016","journal-title":"Drugs"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.ccell.2018.11.004","article-title":"BH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines","volume":"34","author":"Merino","year":"2018","journal-title":"Cancer Cell"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma","volume":"35","author":"Davids","year":"2017","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_143","doi-asserted-by":"crossref","unstructured":"Dengler, M.A., Teh, C.E., Thijssen, R., Gangoda, L., Lan, P., Herold, M.J., Gray, D.H., Kelly, G.L., Roberts, A.W., and Adams, J.M. (2019). Potent efficacy of MCL-1 inhibitor-based therapies in preclinical models of mantle cell lymphoma. Oncogene.","DOI":"10.1038\/s41388-019-1122-x"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/nature19830","article-title":"The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models","volume":"538","author":"Kotschy","year":"2016","journal-title":"Nature"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"458","DOI":"10.3389\/fonc.2018.00458","article-title":"Hematologic Tumor Cell Resistance to the BCL-2 Inhibitor Venetoclax: A Product of Its Microenvironment?","volume":"8","author":"Leverson","year":"2018","journal-title":"Front. Oncol."},{"key":"ref_146","doi-asserted-by":"crossref","unstructured":"Tahir, S.K., Smith, M.L., Hessler, P., Rapp, L.R., Idler, K.B., Park, C.H., Leverson, J.D., and Lam, L.T. (2017). Potential mechanisms of resistance to venetoclax and strategies to circumvent it. BMC Cancer, 17.","DOI":"10.1186\/s12885-017-3383-5"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41591-018-0243-z","article-title":"Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma","volume":"25","author":"Agarwal","year":"2019","journal-title":"Nat. Med."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1038\/s41467-019-10363-1","article-title":"Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations","volume":"10","author":"Birkinshaw","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ccell.2019.08.005","article-title":"Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies","volume":"36","author":"Guieze","year":"2019","journal-title":"Cancer Cell"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/6\/2081\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:07:41Z","timestamp":1760173661000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/6\/2081"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,18]]},"references-count":149,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,3]]}},"alternative-id":["ijms21062081"],"URL":"https:\/\/doi.org\/10.3390\/ijms21062081","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,18]]}}}